Cargando…

Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer

Prostate-specific antigen (PSA) kinetics predicts survival in castration-resistant prostate cancer (CRPC); however, the influence of prior treatment on this relationship is unclear. Patients with CRPC were stratified according to time to PSA nadir and time to CRPC progression to investigate their pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hah, Yoon Soo, Lee, Jong Soo, Rha, Koon Ho, Hong, Sung Joon, Chung, Byung Ha, Koo, Kyo Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695395/ https://www.ncbi.nlm.nih.gov/pubmed/31417160 http://dx.doi.org/10.1038/s41598-019-48424-6

Ejemplares similares

Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy
por: Kim, Do Kyung, et al.
Publicado: (2018)

Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Jang, Ho Seong, et al.
Publicado: (2016)

Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy
por: Ahn, Hyun Kyu, et al.
Publicado: (2020)

Unrecognized Kinetics of Serum Testosterone: Impact on Short-Term Androgen Deprivation Therapy for Prostate Cancer
por: Koo, Kyo Chul, et al.
Publicado: (2014)

Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis
por: Koo, Kyo Chul, et al.
Publicado: (2018)

Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer
por: Koo, Kyo Chul, et al.
Publicado: (2015)

Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis
por: Kim, Do Kyung, et al.
Publicado: (2019)

Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels
por: Koo, Kyo Chul, et al.
Publicado: (2015)

Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
por: Kim, Yejin, et al.
Publicado: (2016)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer
por: Lee, Chung-Lin, et al.
Publicado: (2022)

Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy
por: Heo, Ji Eun, et al.
Publicado: (2018)

Is targeted biopsy really needed when performing systematic prostate biopsy to raise the detection rate for prostate cancer in patients with prostate-specific antigen ≤10 ng/mL?
por: Park, Jee Soo, et al.
Publicado: (2019)

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
por: Decker, Keith F., et al.
Publicado: (2012)

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
por: Min, Kyungchan, et al.
Publicado: (2020)

Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy
por: Teoh, Jeremy YC, et al.
Publicado: (2017)

CPT1A Supports Castration-Resistant Prostate Cancer in Androgen-Deprived Conditions
por: Joshi, Molishree, et al.
Publicado: (2019)

Androgen deprivation-induced OPHN1 amplification promotes castration-resistant prostate cancer
por: Liu, Junjiang, et al.
Publicado: (2022)

Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
por: Marshall, Catherine H., et al.
Publicado: (2021)

Impact of Cerebrovascular Disease on Survival Benefits from Local Treatment in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer
por: Kim, Tae Jin, et al.
Publicado: (2019)

Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy
por: Lin, Yen-Chi, et al.
Publicado: (2021)

The curative effect of androgen deprivation therapy alone is insufficient in high-risk prostate cancer
por: Choi, Se Young, et al.
Publicado: (2021)

Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy
por: Kang, Minyong, et al.
Publicado: (2015)

Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells
por: LIU, TIANCHENG, et al.
Publicado: (2012)

Feasibility of robot-assisted radical prostatectomy for very-high risk prostate cancer: surgical and oncological outcomes in men aged ≥70 years
por: Koo, Kyo Chul, et al.
Publicado: (2014)

Pathophysiology of Bone Loss in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy and Lifestyle Modifications for the Management of Bone Health: A Comprehensive Review
por: Kim, Tae Jin, et al.
Publicado: (2020)

Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
por: Caramella, Irene, et al.
Publicado: (2022)

Analysis of different tumor volume thresholds of insignificant prostate cancer and their implications for active surveillance patient selection and monitoring
por: Lee, Dong Hoon, et al.
Publicado: (2014)

The association of family history of prostate cancer with the diagnosis of clinically significant prostate cancer in Korean population
por: Park, Jee Soo, et al.
Publicado: (2019)

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
por: Hussain, Arif, et al.
Publicado: (2020)

Effects of age and comorbidity on survival vary according to risk grouping among patients with prostate cancer treated using radical prostatectomy: A retrospective competing-risk analysis from the K-CaP registry
por: Hah, Yoon Soo, et al.
Publicado: (2018)

Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy
por: Kim, Ki Bom, et al.
Publicado: (2015)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Comparison of prostate cancer detection rates of various prostate biopsy methods for patients with prostate-specific antigen levels of <10.0 ng/mL in real-world practice
por: Oh, Kyung Tak, et al.
Publicado: (2020)

Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis
por: Park, Jae Won, et al.
Publicado: (2018)

Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence
por: Kim, Dae Keun, et al.
Publicado: (2016)

Peripheral zone prostate-specific antigen density: an effective parameter for prostate cancer prediction in men receiving 5α-reductase inhibitors
por: Koo, Kyo Chul, et al.
Publicado: (2013)

Hypercholesterolemia Is Associated with a Shorter Time to Castration-Resistant Prostate Cancer in Patients Who Have Undergone Androgen Deprivation Therapy
por: Jeon, Jong Chul, et al.
Publicado: (2016)

Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis
por: Afriansyah, Andika, et al.
Publicado: (2018)

A prospective study of the effect of testosterone escape on preradiotherapy prostate-specific antigen kinetics in prostate cancer patients undergoing neoadjuvant androgen deprivation therapy
por: Christie, David R.H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aklrtemmsbkkmablnbgues07ct